Dr. Lal PathLabs Limited IPO Message Board (Page 18)

Pls primium of dr lal path

Powermech return

Founded in 1949,Delhi headquartered Dr. Lal PathLabs Limited is in the business of diagnostic and  healthcare tests  in India. The Company has developed a national network consisting of its National Reference Laboratory in New Delhi, 163  clinical laboratories, 1,340 patient service centers and more than  5,000 pickup points .

The Company offers 3,368 diagnostic and related healthcare tests.Diagnostic and Healthcare Test is the fastest growing segment in Indian Heathcare sector and the Company is well-positioned in the said segment. The  company provides services to individual patients, hospitals and other healthcare providers and  also to corporate customers.
In the year 2014-15, the company had earned total income of Rs. 640 crores and net profit of Rs. 87.97 crores.
This is  the first IPO of a Diagnostic company and hence  is expected to catch fancy of Institutional investors as well as Retail investors and may pave the way for others who have been waiting in the wings ( SRL and Thyrocare ) SRL, a subsidiary of Fortis Healthcare Ltd, had previously filed its documents for an IPO in 2011. Then owned by billionaire brothers Malvinder and Shivinder Singh in their private capacity, the firm was brought under their public listed hospital chain Fortis Healthcare.
Issue Particulars :
Issue Duration : Dec 8, 2015 – Dec 10, 2015
Issue Size: 11,600,000 Equity Shares of Rs. 10
Issue Size: Rs. 626.40 – 638.00 Crores
Face Value: Rs. 10 Per Equity Share
Price Band : Rs. 540 – Rs. 550 Per Equity Share
Market Lot: 20 Shares
Listing proposed at :  NSE & BSE
The Promoters of the company :
1. Dr. Arvind Lal
2. Dr. Vandana Lal
3. Eskay Ho The object of the Offer :
To obtain the benefits of listing the Equity Shares on the Stock Exchanges
Lead Managers :
Citi Group Global and Kotak Mahindra Capital Company
Discussion relating to Valuation and Price Band :
EPS : for the year ended on March 31, 2015  Basic Rs.16.53For the six months ended September 30, 2015, the basic EPS (not annualized) was  Rs. 5.90 and the diluted EPS (not annualized) was Rs 4.47.
Book Value : As on September 30, 2015, Book Value  was Rs.  61.78 per Equity Share on a consolidated basis and  Rs.  57.77 per Equity Share on an unconsolidated basis.
The offer for share at upper price band of Rs. 550 is at PE multiple of 35 on the basis of  estimated EPS of Rs. 19.25 for the year 2015-16.
As retain investor, you  are offered Rs 15 discount on the price band,  so that much will be the gains for  you plus some appreciation on listing , for the  investment  duration of about 10 days. That is  quite attractive.

As per SP Tulsian, Grey Market Premium is 95 to 97.

Sir u r saying its PE multiple of 35 is but according to Uchit Patel P/E ratio is more than 65 please give right information

alkme&drlal grey market rate?

AVOIIIIIIIIIIIIIIIDDDDDDDDDDDDDDDDDDDDD



IT WILL LOOOOOOOOOOOOOOOT U
IT WILL KOOOOOOOOOOOOOOOTTTTT U



LIST AT DISCOUNT
DONT WASTE TIME AND MONEY


Avoiiiiiiiiiiddddddddd
Lochu ipo

Grey Market Premium : 93 to 95
Kostak Price : 1000 to 1100

Price looks high. But there is always problem in calculating industry P/E to compare when any company is going to be list first in it’s segment. This is always a debatable question between analysts also. Sometimes promoters take benefit of this. My experience says at this time consider industry growth potential and company growth.
If we see last IPO - S H Kelkar (P/E more than 32) and industry growth rate is only 5% to 7%. Still investors made money.

Big investors estimated Dr. Lal Pathlab’s value at Rs. 18000 to Rs. 20000 crore for year 2020 while initial stage of funding in year 2006-07. In year 2007 company’s total value was Rs. 100 crore. Post IPO we see total value is about Rs. 6000 crore. If company makes the same growth for next 5 years then no doubt company’s total value reaches Rs. 20000 crore in year 2020.

Market sentiments are also important. At present market sentiments are not bad. Grey market premium is also not bad.
Believe me company will not list in discount. Investors will make some money but not much.

K.p.
give u r contact no..

Ripal rajkot plz give u r contact no...

105 PR...
minimam app 1250 bhv &amb

What is latest premium for Lal??

very pricy

Very Veeeeryyyyyy High Cost of Issue Price

Gmp discount 34 RS

APPLICATION NO BUYEEEEEEERRRRRR
LATESTTTTT NEWSSSSS


ONLY SELLLLLLLLLLLLLLEREEEEEERRRR
SELL SELLSELLLSELLLSELLLSELLLLLLL

15 RS DISCOUNT IT WILLLLL LOOOOTTTTTT


JHASE MAIN NI AYEGNE ALKEM MAIN HI LAGAENGE

ahmedabad ipo

please share ur number for contact

Humko 11 mulko ka police dhund rahi ha

Busy in filing DRHP of book my show for 300cr ipo

Retail discount is bogus
Clear cut AVOID ASKING 50 PE

AVOOOOOOOOOIIIIIIIIIIDDDDDDDDDDDDD

Jhand fhakir ipo
550/11eps hoge 50 PE toh Choudhary ji samjhi ipo kai baare main


Avvvvvvvvvvoooooooooooooouiiiiiiiiiiiiiiiiiiiiiiddddfdffffff





It will looooooooooot uuuuu
It will kooooooooooot uuuuuuuu

kya hua loot you koot you pinky.........

its highly open value IPO in this year 50% UP in single Day. ...

pinky jain :( :( :(

Dr. Lal Path LAB :) :) :)

MUMBAI, NOV 30:
Medical diagnostics chain Dr Lal Pathlabs is making an initial public offer next week. The company is placing 1.16 crore equity shares of face value of Rs. 10 each on the block through an offer for sale in the price band of Rs. 540-550. The total offer size is Rs. 620 crore – 630 crore.

The company offers about 3,495 diagnostic and healthcare tests, including routine clinical tests, specialised tests (for instance, in genetics) and preventive testing for diseases such as hypertension. It has an 80,000-sq ft national reference laboratory in New Delhi and 171 other standalone “satellite” labs. The network of labs is concentrated in the northern and eastern regions, with labs in all major cities.

The minimum bid lot is for 20 equity shares and thereafter in multiples of 20 equity shares. The offer opens on December 8 and closes on December 10. The book running lead managers are Kotak Mahindra Capital and Citigroup Global Markets India Pvt Ltd. The shares are proposed to be listed on the NSE and the BSE. The company is offering a discount of up to Rs. 15 on the offer price to retail individual bidders.

Some of my analysis of Dr. Lal PathLabs IPO:

It is more than 65 years old company. Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Company has National Reference Laboratory in New Delhi, 163 other clinical laboratories, 1,340 patient service centers and over 5,000 pickup points. Strong customer base include individual patients, hospitals and other healthcare providers and corporate employees. The IPO would make it one of the first prominent diagnostic chains to go public. This IPO may make way for others who have been waiting in the wings such as SRL and Thyrocare. The firm is four-fifth the size of bigger rival SRL.

Dates of IPO – 8th December, 2015 to 10th December, 2015.
Price band – Rs. 540 to Rs. 550.
Lot size –20.

Promoters are planning to sell 14.1%( main promoter plans to divest 5%, while other investors such as Wagner Ltd and Westbridge Crossover Fund will divest 9.1%) of their stake. Promoters are looking valuation of Rs 6000 crore post IPO Objective of this IPO is to achieve the benefits of listing the Equity Shares on the Stock Exchanges. The company will not receive any proceeds from the offer. Objective is not convincing to me.

I have last 4 years financial data. From 2012 to 2015 company’s income increases from 3199 million Rs to 6401 million Rs. It shows almost 25% increase each year. It shows excellent growth. Net profit is 410 million Rs in 2012 and 879 million Rs in 2015. It shows 100% increase in net profit in four years.

In 2005, Dr Lal PathLabs had only 10 laboratories and revenue of around Rs 45 crore. It’s value was Rs 100 crore in 2007. The company was valued in between Rs 1500 crore to Rs 1750 crore in its last round of funding in 2013. The business has been growing at an annual growth rate of 25%.

If we see the Rs. 6000 crore value post IPO, it is available at more than 65 P/E ratio. It is very high.

Market sentiments are also important at the time of listing. I think Dr. Lal will list on fourth week of December, 2015. Major two events will drive market at that time GST bill and Fed rate hike. I think GST bill will pass. Fed will increase rate by 25 bps points on 16th December meeting. Post rate increase dollar is going to be strong compare to euro and other currencies, emerging markets will be weak. However, India is best choice of foreign investors becaof constant economic reform.

Grey market premium is also not bad. Today (30th November, 2015) in Ahmedabad grey market premium is Rs. 900. Real buyer and seller. Real transactions.

Some positives about this company:

Constant growth in the company and health care industry, first company in it’s segment going to be list, good grey market premium. Favorable market sentiments at the time of listing.

Concerns about this company:

Price is very high. Company is not getting anything from IPO. Long time investors are selling their stake.

I suggest don’t avoid this IPO. Apply for only 1 or 2 application. Favorable market sentiments will help this IPO to list in positive. Long term this company will give good returns.

However, this company is going to hit the market with Alkem Lab. I suggest everyone to apply with full capacity in Alkem Lab. Also, keep money for Coal India OFS. It will hit market anytime.

Sir u r saying its PE multiple of 65 is but according to . Rajeev Kumar Singh P/E ratio is 35 please give right information.

Hasija, P/E is coming more than 50.
EPS data is not available. But I calculated by following data:
Company is selling 14.1% of share (total 11600000 shares in 14.1%). If we count total shares for 100% it comes to 82269503. Net profit for year 2015 is 879000000.
Now EPS = 879000000/82269503 = 10.68
Now P/E = 550/10.68 = 51.49

Its good to sale in grey market or keep own ?

it seems costly due to eps is only 16 rupees. bechkar lgane m fayda rahega

fundamental this looks avoid they looking at valuation close to 4500 cr on a profit of 88 cr making a PE of close to 52 correct me if i am wrong issue size is 638 cr which is around 14% of total company so at 100% is 4500. AVOID AVOID AVOID